메뉴 건너뛰기




Volumn 12, Issue 6, 2014, Pages 916-946

Non-Hodgkin's lymphomas, version 2.2014

(34)  Zelenetz, Andrew D a   Gordon, Leo I b   Wierda, William G c   Abramson, Jeremy S d   Advani, Ranjana H e   Andreadis, C Babis f   Bartlett, Nancy g   Bellam, Naresh h   Byrd, John C i   Czuczman, Myron S j   Fayad, Luis E d   Fisher, Richard I k   Glenn, Martha J l   Harris, Nancy Lee d   Hoppe, Richard T e   Horwitz, Steven M a   Kelsey, Christopher R m   Kim, Youn H e   Krivacic, Susan y   LaCasce, Ann S n   more..


Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 84902504593     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0086     Document Type: Review
Times cited : (58)

References (127)
  • 2
    • 0034596366 scopus 로고    scopus 로고
    • Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995
    • Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-1251. (Pubitemid 30627732)
    • (2000) Journal of the National Cancer Institute , vol.92 , Issue.15 , pp. 1240-1251
    • Groves, F.D.1    Linet, M.S.2    Travis, L.B.3    Devesa, S.S.4
  • 3
    • 1842413105 scopus 로고    scopus 로고
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
    • (1997) Blood , vol.89 , pp. 3909-3918
  • 4
    • 85047279202 scopus 로고    scopus 로고
    • The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma
    • Koster A, Tromp HA, Raemaekers JM, et al. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007;92:184-190.
    • (2007) Haematologica , vol.92 , pp. 184-190
    • Koster, A.1    Tromp, H.A.2    Raemaekers, J.M.3
  • 7
    • 62449324950 scopus 로고    scopus 로고
    • Follicular lymphoma in the United States: First report of the national LymphoCare study
    • Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202-1208.
    • (2009) J Clin Oncol , vol.27 , pp. 1202-1208
    • Friedberg, J.W.1    Taylor, M.D.2    Cerhan, J.R.3
  • 8
    • 70349745593 scopus 로고    scopus 로고
    • Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
    • Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
    • (2009) J Clin Oncol , vol.27 , pp. 4555-4562
    • Federico, M.1    Bellei, M.2    Marcheselli, L.3
  • 9
    • 84873397196 scopus 로고    scopus 로고
    • Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
    • Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013;31:314-320.
    • (2013) J Clin Oncol , vol.31 , pp. 314-320
    • Press, O.W.1    Unger, J.M.2    Rimsza, L.M.3
  • 10
    • 84890284204 scopus 로고    scopus 로고
    • A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine - tositumomab
    • Press OW, Unger JM, Rimsza LM, et al. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine - tositumomab. Clin Cancer Res 2013;19:6624-6632.
    • (2013) Clin Cancer Res , vol.19 , pp. 6624-6632
    • Press, O.W.1    Unger, J.M.2    Rimsza, L.M.3
  • 11
    • 0036566185 scopus 로고    scopus 로고
    • In situ localization of follicular lymphoma: Description and analysis by laser capture microdissection
    • DOI 10.1182/blood.V99.9.3376
    • Cong P, Raffeld M, Teruya-Feldstein J, et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002;99:3376-3382. (Pubitemid 34525319)
    • (2002) Blood , vol.99 , Issue.9 , pp. 3376-3382
    • Cong, P.1    Raffeid, M.2    Teruya-Feldstein, J.3    Sorbara, L.4    Pittaluga, S.5    Jaffe, E.S.6
  • 13
    • 79960366619 scopus 로고    scopus 로고
    • In situ follicular lymphoma: Pathologic characteristics and diagnostic features
    • Carbone A, Gloghini A, Santoro A. In situ follicular lymphoma: pathologic characteristics and diagnostic features. Hematol Oncol 2012;30:1-7.
    • (2012) Hematol Oncol , vol.30 , pp. 1-7
    • Carbone, A.1    Gloghini, A.2    Santoro, A.3
  • 14
    • 34548274589 scopus 로고    scopus 로고
    • In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach
    • DOI 10.1016/j.yexmp.2007.03.001, PII S001448000700038X
    • Sotomayor EA, Shah IM, Sanger WG, Mark HF. In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach. Exp Mol Pathol 2007;83:254-258. (Pubitemid 47320652)
    • (2007) Experimental and Molecular Pathology , vol.83 , Issue.2 , pp. 254-258
    • Sotomayor, E.A.1    Shah, I.M.2    Sanger, W.G.3    Mark, H.F.L.4
  • 15
    • 79960451484 scopus 로고    scopus 로고
    • Prevalence of follicular lymphoma in situ in consecutively analysed reactive lymph nodes
    • Henopp T, Quintanilla-Martinez L, Fend F, Adam P. Prevalence of follicular lymphoma in situ in consecutively analysed reactive lymph nodes. Histopathology 2011;59:139-142.
    • (2011) Histopathology , vol.59 , pp. 139-142
    • Henopp, T.1    Quintanilla-Martinez, L.2    Fend, F.3    Adam, P.4
  • 16
    • 80052882229 scopus 로고    scopus 로고
    • Follicular lymphoma in situ: Clinical implications and comparisons with partial involvement by follicular lymphoma
    • Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011;118:2976-2984.
    • (2011) Blood , vol.118 , pp. 2976-2984
    • Jegalian, A.G.1    Eberle, F.C.2    Pack, S.D.3
  • 17
    • 84884949944 scopus 로고    scopus 로고
    • Follicular lymphoma-like B-cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies
    • Pillai RK, Surti U, Swerdlow SH. Follicular lymphoma-like B-cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica 2013;98:1571-1580.
    • (2013) Haematologica , vol.98 , pp. 1571-1580
    • Pillai, R.K.1    Surti, U.2    Swerdlow, S.H.3
  • 18
    • 80053182395 scopus 로고    scopus 로고
    • A unique case of follicular lymphoma provides insights to the clonal evolution from follicular lymphoma in situ to manifest follicular lymphoma
    • Bonzheim I, Salaverria I, Haake A, et al. A unique case of follicular lymphoma provides insights to the clonal evolution from follicular lymphoma in situ to manifest follicular lymphoma. Blood 2011;118:3442-3444.
    • (2011) Blood , vol.118 , pp. 3442-3444
    • Bonzheim, I.1    Salaverria, I.2    Haake, A.3
  • 19
    • 0018731097 scopus 로고
    • Follicular (nodular) lymphoma in childhood: A rare clinical-pathological entity. Report of 8 cases from 4 cancer centres
    • DOI 10.1002/1097-0142(197912)44:6<2218::AID-CNCR28
    • Frizzera G, Murphy SB. Follicular (nodular) lymphoma in childhood: a rare clinical-pathological entity. Report of eight cases from four cancer centers. Cancer 1979;44:2218-2235. (Pubitemid 10210852)
    • (1979) Cancer , vol.44 , Issue.6 , pp. 2218-2235
    • Frizzera, G.1    Murphy, S.B.2
  • 21
    • 76549123434 scopus 로고    scopus 로고
    • Pediatric follicular lymphoma - A clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma - Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials
    • Oschlies I, Salaverria I, Mahn F, et al. Pediatric follicular lymphoma - a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma - Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 2010;95:253-259.
    • (2010) Haematologica , vol.95 , pp. 253-259
    • Oschlies, I.1    Salaverria, I.2    Mahn, F.3
  • 22
    • 0026803006 scopus 로고
    • Childhood malignant non-Hodgkin lymphomas of uncommon histology
    • Ribeiro RC, Pui CH, Murphy SB, et al. Childhood malignant non-Hodgkin lymphomas of uncommon histology. Leukemia 1992;6:761-765.
    • (1992) Leukemia , vol.6 , pp. 761-765
    • Ribeiro, R.C.1    Pui, C.H.2    Murphy, S.B.3
  • 23
    • 84874000285 scopus 로고    scopus 로고
    • Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma
    • Liu Q, Salaverria I, Pittaluga S, et al. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013;37:333-343.
    • (2013) Am J Surg Pathol , vol.37 , pp. 333-343
    • Liu, Q.1    Salaverria, I.2    Pittaluga, S.3
  • 24
    • 84866628707 scopus 로고    scopus 로고
    • Pediatric-type nodal follicular lymphoma: An indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement
    • Louissaint A Jr, Ackerman AM, Dias-Santagata D, et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood 2012;120:2395-2404.
    • (2012) Blood , vol.120 , pp. 2395-2404
    • Louissaint Jr., A.1    Ackerman, A.M.2    Dias-Santagata, D.3
  • 25
    • 79958782287 scopus 로고    scopus 로고
    • Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma
    • Kumar R, Galardy PJ, Dogan A, et al. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma. Pediatr Blood Cancer 2011;57:317-320.
    • (2011) Pediatr Blood Cancer , vol.57 , pp. 317-320
    • Kumar, R.1    Galardy, P.J.2    Dogan, A.3
  • 26
    • 0034809468 scopus 로고    scopus 로고
    • Bone marrow trephine biopsy
    • Bain BJ. Bone marrow trephine biopsy. J Clin Pathol 2001;54:737-742. (Pubitemid 32929492)
    • (2001) Journal of Clinical Pathology , vol.54 , Issue.10 , pp. 737-742
    • Bain, B.J.1
  • 28
    • 23044469098 scopus 로고    scopus 로고
    • 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
    • DOI 10.1200/JCO.2005.12.072
    • Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643-4651. (Pubitemid 46224066)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.21 , pp. 4643-4651
    • Schoder, H.1    Noy, A.2    Gonen, M.3    Weng, L.4    Green, D.5    Erdi, Y.E.6    Larson, S.M.7    Yeung, H.W.D.8
  • 29
    • 77956854938 scopus 로고    scopus 로고
    • Long-term outcomes for patients with limited stage follicular lymphoma: Involved regional radiotherapy versus involved node radiotherapy
    • Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 2010;116:3797-3806.
    • (2010) Cancer , vol.116 , pp. 3797-3806
    • Campbell, B.A.1    Voss, N.2    Woods, R.3
  • 31
    • 0006987727 scopus 로고    scopus 로고
    • Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University
    • Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:1282-1290. (Pubitemid 26105537)
    • (1996) Journal of Clinical Oncology , vol.14 , Issue.4 , pp. 1282-1290
    • Mac, M.M.P.1    Hoppe, R.T.2
  • 33
    • 2342560524 scopus 로고    scopus 로고
    • Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
    • DOI 10.1200/JCO.2004.10.086
    • Advani R, Rosenberg S, Horning S. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004;22:1454-1459. (Pubitemid 41103628)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.8 , pp. 1454-1459
    • Advani, R.1    Rosenberg, S.A.2    Horning, S.J.3
  • 34
    • 0025979505 scopus 로고
    • Stage I-II low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy
    • McLaughlin P, Fuller L, Redman J, et al. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol 1991;2(Suppl 2):137-140.
    • (1991) Ann Oncol , vol.2 , Issue.SUPPL. 2 , pp. 137-140
    • McLaughlin, P.1    Fuller, L.2    Redman, J.3
  • 35
    • 0027409814 scopus 로고
    • Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate- grade non-Hodgkin lymphoma: Results of a prospective randomized study
    • Yahalom J, Varsos G, Fuks Z, et al. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 1993;71:2342-2350. (Pubitemid 23087778)
    • (1993) Cancer , vol.71 , Issue.7 , pp. 2342-2350
    • Yahalom, J.1    Varsos, G.2    Fuks, Z.3    Myers, J.4    Clarkson, B.D.5    Straus, D.J.6
  • 36
    • 84866745624 scopus 로고    scopus 로고
    • Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National LymphoCare Study
    • Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012;30:3368-3375.
    • (2012) J Clin Oncol , vol.30 , pp. 3368-3375
    • Friedberg, J.W.1    Byrtek, M.2    Link, B.K.3
  • 37
    • 84879490270 scopus 로고    scopus 로고
    • Early stage follicular lymphoma: What is the clinical impact of the first-line treatment strategy?
    • Michallet AS, Lebras LL, Bauwens DD, et al. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? J Hematol Oncol 2013;6:45.
    • (2013) J Hematol Oncol , vol.6 , pp. 45
    • Michallet, A.S.1    Lebras, L.L.2    Bauwens, D.D.3
  • 38
    • 0023992626 scopus 로고
    • The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment
    • Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:11-16.
    • (1988) Semin Hematol , vol.25 , pp. 11-16
    • Young, R.C.1    Longo, D.L.2    Glatstein, E.3
  • 39
    • 0031050192 scopus 로고    scopus 로고
    • Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires
    • Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-1117. (Pubitemid 27106296)
    • (1997) Journal of Clinical Oncology , vol.15 , Issue.3 , pp. 1110-1117
    • Brice, P.1    Bastion, Y.2    Lepage, E.3    Brousse, N.4    Haioun, C.5    Moreau, P.6    Straetmans, N.7    Tilly, H.8    Tabah, I.9    Solal-Celigny, P.10
  • 40
    • 0041656437 scopus 로고    scopus 로고
    • Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial
    • DOI 10.1016/S0140-6736(03)14110-4
    • Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-522. (Pubitemid 36976715)
    • (2003) Lancet , vol.362 , Issue.9383 , pp. 516-522
    • Ardeshna, K.M.1    Smith, P.2    Norton, A.3    Hancock, B.W.4    Hoskin, P.J.5    MacLennan, K.A.6    Marcus, R.E.7    Jelliffe, A.8    Vaughan, H.G.9    Linch, D.C.10
  • 41
    • 78951481506 scopus 로고    scopus 로고
    • An Intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis
    • [abstract]. Abstact 6
    • Ardeshna K, Qian W, Smith P, et al. An Intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood 2010;116:Abstact 6.
    • (2010) Blood , vol.116
    • Ardeshna, K.1    Qian, W.2    Smith, P.3
  • 42
    • 84867400613 scopus 로고    scopus 로고
    • Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma
    • [abstract]. Abstract LBA-6
    • Kahl BS, Hong F, Williams ME, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]. Blood 2011;118:Abstract LBA-6.
    • (2011) Blood , vol.118
    • Kahl, B.S.1    Hong, F.2    Williams, M.E.3
  • 43
    • 84869109856 scopus 로고    scopus 로고
    • Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: Results of an F2-study database
    • Solal-Celigny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012;30:3848-3853.
    • (2012) J Clin Oncol , vol.30 , pp. 3848-3853
    • Solal-Celigny, P.1    Bellei, M.2    Marcheselli, L.3
  • 48
    • 13244288836 scopus 로고    scopus 로고
    • Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-Year follow-up
    • Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-4716.
    • (2004) J Clin Oncol , vol.22 , pp. 4711-4716
    • Czuczman, M.S.1    Weaver, R.2    Alkuzweny, B.3
  • 51
    • 53749085410 scopus 로고    scopus 로고
    • Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    • Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-4586.
    • (2008) J Clin Oncol , vol.26 , pp. 4579-4586
    • Marcus, R.1    Imrie, K.2    Solal-Celigny, P.3
  • 53
    • 34249805964 scopus 로고    scopus 로고
    • Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma: Results of a prospective randomized trial of the german low grade lymphoma study group (GLSG)
    • [abstract]. Abstract 482
    • Buske C, Kneba M, Lengfelder E, et al. Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma: results of a prospective randomized trial of the german low grade lymphoma study group (GLSG) [abstract]. Blood 2006;108:Abstract 482.
    • (2006) Blood , pp. 108
    • Buske, C.1    Kneba, M.2    Lengfelder, E.3
  • 55
    • 8744274334 scopus 로고    scopus 로고
    • The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • DOI 10.1182/blood-2004-04-1323
    • Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071. (Pubitemid 39517009)
    • (2004) Blood , vol.104 , Issue.10 , pp. 3064-3071
    • Forstpointner, R.1    Dreyling, M.2    Repp, R.3    Hermann, S.4    Hanel, A.5    Metzner, B.6    Pott, C.7    Hartmann, F.8    Rothmann, F.9    Rohrberg, R.10    Bock, H.-P.11    Wandt, H.12    Unterhalt, M.13    Hiddemann, W.14
  • 59
    • 77957337432 scopus 로고    scopus 로고
    • Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: A multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS)
    • Morschhauser F, Mounier N, Sebban C, et al. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS). Cancer 2010;116:4299-4308.
    • (2010) Cancer , vol.116 , pp. 4299-4308
    • Morschhauser, F.1    Mounier, N.2    Sebban, C.3
  • 60
    • 84865835283 scopus 로고    scopus 로고
    • A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States
    • [abstract]. Abstract 97
    • Nastoupil L, Sinha R, Byrtek M, et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States [abstract]. Blood 2011;118:Abstract 97.
    • (2011) Blood , pp. 118
    • Nastoupil, L.1    Sinha, R.2    Byrtek, M.3
  • 61
    • 84876578455 scopus 로고    scopus 로고
    • R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi
    • Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013;31:1506-1513.
    • (2013) J Clin Oncol , vol.31 , pp. 1506-1513
    • Federico, M.1    Luminari, S.2    Dondi, A.3
  • 62
    • 33747061875 scopus 로고    scopus 로고
    • Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia
    • DOI 10.1200/JCO.2006.06.0673
    • Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006;24:3604-3610. (Pubitemid 46630533)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.22 , pp. 3604-3610
    • Kalaycio, M.1    Rybicki, L.2    Pohlman, B.3    Sobecks, R.4    Andresen, S.5    Kuczkowski, E.6    Bolwell, B.7
  • 64
    • 0034585610 scopus 로고    scopus 로고
    • Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma
    • Micallef IN, Apostolidis J, Rohatiner AZ, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000;1:367-373.
    • (2000) Hematol J , vol.1 , pp. 367-373
    • Micallef, I.N.1    Apostolidis, J.2    Rohatiner, A.Z.3
  • 65
    • 80052746696 scopus 로고    scopus 로고
    • Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study
    • Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011;29:3389-3395.
    • (2011) J Clin Oncol , vol.29 , pp. 3389-3395
    • Fowler, N.1    Kahl, B.S.2    Lee, P.3
  • 66
    • 79953077610 scopus 로고    scopus 로고
    • The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    • Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807-2812.
    • (2011) Blood , vol.117 , pp. 2807-2812
    • Friedberg, J.W.1    Vose, J.M.2    Kelly, J.L.3
  • 67
    • 38349119981 scopus 로고    scopus 로고
    • Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
    • Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-210.
    • (2008) J Clin Oncol , vol.26 , pp. 204-210
    • Friedberg, J.W.1    Cohen, P.2    Chen, L.3
  • 68
    • 74549225036 scopus 로고    scopus 로고
    • Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study
    • Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106-114.
    • (2010) Cancer , vol.116 , pp. 106-114
    • Kahl, B.S.1    Bartlett, N.L.2    Leonard, J.P.3
  • 69
    • 52649177173 scopus 로고    scopus 로고
    • Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    • Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-4479.
    • (2008) J Clin Oncol , vol.26 , pp. 4473-4479
    • Robinson, K.S.1    Williams, M.E.2    Van Der Jagt, R.H.3
  • 70
    • 79955446566 scopus 로고    scopus 로고
    • Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - Final results of the randomized phase III study NHL 2-2003 on behalf of the StiL
    • (Study Group Indolent Lymphomas, Germany) [abstract]. Abstract 856
    • Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood 2010;116:Abstract 856.
    • (2010) Blood , pp. 116
    • Rummel, M.J.1    Kaiser, U.2    Balser, C.3
  • 71
    • 84875840492 scopus 로고    scopus 로고
    • Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial
    • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-1210.
    • (2013) Lancet , vol.381 , pp. 1203-1210
    • Rummel, M.J.1    Niederle, N.2    Maschmeyer, G.3
  • 72
    • 84878111837 scopus 로고    scopus 로고
    • An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study
    • [abstract]. Abstract 902
    • Flinn IW, Van der Jagt RH, Kahl BS, et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): the Bright study [abstract]. Blood 2012;120:Abstract 902.
    • (2012) Blood , pp. 120
    • Flinn, I.W.1    Van Der Jagt, R.H.2    Kahl, B.S.3
  • 73
    • 73949145763 scopus 로고    scopus 로고
    • Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
    • Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:5404-5409.
    • (2009) J Clin Oncol , vol.27 , pp. 5404-5409
    • Witzig, T.E.1    Wiernik, P.H.2    Moore, T.3
  • 74
    • 84868193664 scopus 로고    scopus 로고
    • CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma
    • [abstract]. Abstract 8000
    • Leonard J, Jung SH, Johnson JL, et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 8000.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Leonard, J.1    Jung, S.H.2    Johnson, J.L.3
  • 75
    • 84875922053 scopus 로고    scopus 로고
    • Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase II study
    • [abstract]. Abstract 901
    • Fowler NH, Neelapu SS, Hagemeister FB, et al. Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study [abstract]. Blood 2012;120:Abstract 901.
    • (2012) Blood , pp. 120
    • Fowler, N.H.1    Neelapu, S.S.2    Hagemeister, F.B.3
  • 79
    • 84862227268 scopus 로고    scopus 로고
    • 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. First results from an international phase II clinical trial
    • [abstract]. Abstract 593
    • Scholz CW, Pinto A, Linkesch W, et al. 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. first results from an international phase II clinical trial [abstract]. Blood 2010;116:Abstract 593.
    • (2010) Blood , pp. 116
    • Scholz, C.W.1    Pinto, A.2    Linkesch, W.3
  • 80
    • 84873368418 scopus 로고    scopus 로고
    • (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 Months of follow-up data from an international multicenter phase II clinical trial
    • Scholz CW, Pinto A, Linkesch W, et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013;31:308-313.
    • (2013) J Clin Oncol , vol.31 , pp. 308-313
    • Scholz, C.W.1    Pinto, A.2    Linkesch, W.3
  • 83
    • 0035478728 scopus 로고    scopus 로고
    • Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
    • Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3328.
    • (2001) J Clin Oncol , vol.19 , pp. 3918-13328
    • Kaminski, M.S.1    Zelenetz, A.D.2    Press, O.W.3
  • 84
    • 14144249536 scopus 로고    scopus 로고
    • Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab
    • DOI 10.1200/JCO.2005.07.040
    • Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-719. (Pubitemid 46224170)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.4 , pp. 712-719
    • Horning, S.J.1    Younes, A.2    Jain, V.3    Kroll, S.4    Lucas, J.5    Podoloff, D.6    Goris, M.7
  • 85
    • 77954139787 scopus 로고    scopus 로고
    • Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: Median 10 year follow-up results
    • [abstract]. Abstract 3759
    • Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results [abstract]. Blood 2009;114:Abstract 3759.
    • (2009) Blood , pp. 114
    • Kaminski, M.S.1    Tuck, M.2    Estes, J.3
  • 86
    • 79955835520 scopus 로고    scopus 로고
    • Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low-grade and transformed B-cell lymphomas
    • [abstract]. Abstract 3960
    • Kaminski MS, Zelenetz AD, Press OW, et al. Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low-grade and transformed B-cell lymphomas [abstract]. Blood 2010;116:Abstract 3960.
    • (2010) Blood , pp. 116
    • Kaminski, M.S.1    Zelenetz, A.D.2    Press, O.W.3
  • 87
    • 69149103542 scopus 로고    scopus 로고
    • Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: A phase II trial of the Sarah Cannon Oncology Research Consortium
    • Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009;9:223-228.
    • (2009) Clin Lymphoma Myeloma , vol.9 , pp. 223-228
    • Hainsworth, J.D.1    Spigel, D.R.2    Markus, T.M.3
  • 88
    • 58149237828 scopus 로고    scopus 로고
    • Phase II trial of shortcourse CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma
    • Jacobs SA, Swerdlow SH, Kant J, et al. Phase II trial of shortcourse CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088-7094.
    • (2008) Clin Cancer Res , vol.14 , pp. 7088-7094
    • Jacobs, S.A.1    Swerdlow, S.H.2    Kant, J.3
  • 89
    • 55949118446 scopus 로고    scopus 로고
    • Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
    • Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
    • (2008) J Clin Oncol , vol.26 , pp. 5156-5164
    • Morschhauser, F.1    Radford, J.2    Van Hoof, A.3
  • 90
    • 40949165029 scopus 로고    scopus 로고
    • Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: A phase II non-randomised trial (FLUMIZ)
    • Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008;9:352-358.
    • (2008) Lancet Oncol , vol.9 , pp. 352-358
    • Zinzani, P.L.1    Tani, M.2    Pulsoni, A.3
  • 91
    • 24944462403 scopus 로고    scopus 로고
    • Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    • Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-5704.
    • (2005) J Clin Oncol , vol.23 , pp. 5696-5704
    • Leonard, J.P.1    Coleman, M.2    Kostakoglu, L.3
  • 92
    • 33748671762 scopus 로고    scopus 로고
    • Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
    • DOI 10.1200/JCO.2006.05.8198
    • Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-4149. (Pubitemid 46622291)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.25 , pp. 4143-4149
    • Press, O.W.1    Unger, J.M.2    Braziel, R.M.3    Maloney, D.G.4    Miller, T.P.5    LeBlanc, M.6    Fisher, R.I.7
  • 93
    • 0041440084 scopus 로고    scopus 로고
    • A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
    • DOI 10.1182/blood-2003-01-0287
    • Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102:1606-1612. (Pubitemid 37022549)
    • (2003) Blood , vol.102 , Issue.5 , pp. 1606-1612
    • Press, O.W.1    Unger, J.M.2    Braziel, R.M.3    Maloney, D.G.4    Miller, T.P.5    LeBlanc, M.6    Gaynor, E.R.7    Rivkin, S.E.8    Fisher, R.I.9
  • 94
    • 77954599254 scopus 로고    scopus 로고
    • Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter phase II study
    • Link BK, Martin P, Kaminski MS, et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010;28:3035-3041.
    • (2010) J Clin Oncol , vol.28 , pp. 3035-3041
    • Link, B.K.1    Martin, P.2    Kaminski, M.S.3
  • 95
    • 84880657268 scopus 로고    scopus 로고
    • 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-Line Indolent Trial
    • Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-Line Indolent Trial. J Clin Oncol 2013;31:1977-1983.
    • (2013) J Clin Oncol , vol.31 , pp. 1977-1983
    • Morschhauser, F.1    Radford, J.2    Van Hoof, A.3
  • 97
    • 78650823810 scopus 로고    scopus 로고
    • Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
    • Martinelli G, Hsu Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:4480-4484.
    • (2010) J Clin Oncol , vol.28 , pp. 4480-4484
    • Martinelli, G.1    Hsu Schmitz, S.F.2    Utiger, U.3
  • 98
    • 79955858210 scopus 로고    scopus 로고
    • Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03
    • Taverna CJ, Bassi S, Hitz F, et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. Blood 2010;116:1802.
    • (2010) Blood , vol.116 , pp. 1802
    • Taverna, C.J.1    Bassi, S.2    Hitz, F.3
  • 99
    • 14544276412 scopus 로고    scopus 로고
    • Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the Minnie Pearl Cancer Research Network
    • DOI 10.1200/JCO.2005.12.191
    • Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-1095. (Pubitemid 46202263)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.6 , pp. 1088-1095
    • Hainsworth, J.D.1    Litchy, S.2    Shaffer, D.W.3    Van Lackey, L.4    Grimaldi, M.5    Greco, F.A.6
  • 100
    • 63749097149 scopus 로고    scopus 로고
    • Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study
    • Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-1614.
    • (2009) J Clin Oncol , vol.27 , pp. 1607-1614
    • Hochster, H.1    Weller, E.2    Gascoyne, R.D.3
  • 101
    • 78650823247 scopus 로고    scopus 로고
    • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial
    • Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
    • (2011) Lancet , vol.377 , pp. 42-51
    • Salles, G.1    Seymour, J.F.2    Offner, F.3
  • 102
    • 33845515497 scopus 로고    scopus 로고
    • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
    • DOI 10.1182/blood-2006-04-016725
    • Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008. (Pubitemid 44920177)
    • (2006) Blood , vol.108 , Issue.13 , pp. 4003-4008
    • Forstpointner, R.1    Unterhalt, M.2    Dreyling, M.3    Bock, H.-P.4    Repp, R.5    Wandt, H.6    Pott, C.7    Seymour, J.F.8    Metzner, B.9    Hanel, A.10    Lehmann, T.11    Hartmann, F.12    Einsele, H.13    Hiddemann, W.14
  • 104
    • 77956413908 scopus 로고    scopus 로고
    • Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study
    • van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-2858.
    • (2010) J Clin Oncol , vol.28 , pp. 2853-2858
    • Van Oers, M.H.1    Van Glabbeke, M.2    Giurgea, L.3
  • 108
    • 49049104011 scopus 로고    scopus 로고
    • Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study
    • Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614-3620.
    • (2008) J Clin Oncol , vol.26 , pp. 3614-3620
    • Sebban, C.1    Brice, P.2    Delarue, R.3
  • 111
    • 38149063716 scopus 로고    scopus 로고
    • Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning
    • Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008;14:236-245.
    • (2008) Biol Blood Marrow Transplant , vol.14 , pp. 236-245
    • Hari, P.1    Carreras, J.2    Zhang, M.J.3
  • 113
    • 0037677687 scopus 로고    scopus 로고
    • 18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma
    • Blum RH, Seymour JF, Wirth A, et al. Frequent impact of [18F] fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:43-49. (Pubitemid 36826876)
    • (2003) Clinical Lymphoma , vol.4 , Issue.1 , pp. 43-49
    • Blum, R.H.1    Seymour, J.F.2    Wirth, A.3    MacManus, M.4    Hicks, R.J.5
  • 114
    • 33745322847 scopus 로고    scopus 로고
    • Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas
    • DOI 10.1002/cncr.21967
    • Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175-183. (Pubitemid 43939045)
    • (2006) Cancer , vol.107 , Issue.1 , pp. 175-183
    • Karam, M.1    Novak, L.2    Cyriac, J.3    Ali, A.4    Nazeer, T.5    Nugent, F.6
  • 115
    • 33646181100 scopus 로고    scopus 로고
    • 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading
    • Wohrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780-784.
    • (2006) Ann Oncol , vol.17 , pp. 780-784
    • Wohrer, S.1    Jaeger, U.2    Kletter, K.3
  • 116
    • 58149330642 scopus 로고    scopus 로고
    • Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma?
    • Janikova A, Bolcak K, Pavlik T, et al. Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma 2008;8:287-293.
    • (2008) Clin Lymphoma Myeloma , vol.8 , pp. 287-293
    • Janikova, A.1    Bolcak, K.2    Pavlik, T.3
  • 118
    • 78649779944 scopus 로고    scopus 로고
    • Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma
    • Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37:2307-2314.
    • (2010) Eur J Nucl Med Mol Imaging , vol.37 , pp. 2307-2314
    • Le Dortz, L.1    De Guibert, S.2    Bayat, S.3
  • 119
    • 80051821494 scopus 로고    scopus 로고
    • Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants
    • Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011;29:3194-3200.
    • (2011) J Clin Oncol , vol.29 , pp. 3194-3200
    • Trotman, J.1    Fournier, M.2    Lamy, T.3
  • 120
    • 84870735307 scopus 로고    scopus 로고
    • Impact of [(18) F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS
    • Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18) F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with
    • (2012) J Clin Oncol , vol.30 , pp. 4317-4322
    • Dupuis, J.1    Berriolo-Riedinger, A.2    Julian, A.3
  • 121
    • 61649111160 scopus 로고    scopus 로고
    • The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)
    • Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20:508-512.
    • (2009) Ann Oncol , vol.20 , pp. 508-512
    • Noy, A.1    Schoder, H.2    Gonen, M.3
  • 122
    • 0032926756 scopus 로고    scopus 로고
    • Stages I-III follicular lymphoma: Role of CT of the abdomen and pelvis in follow-up studies
    • Oh YK, Ha CS, Samuels BI, et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 1999;210:483-486. (Pubitemid 29055319)
    • (1999) Radiology , vol.210 , Issue.2 , pp. 483-486
    • Oh, Y.K.1    Ha, C.S.2    Samuels, B.I.3    Cabanillas, F.4    Hess, M.A.5    Cox, J.D.6
  • 123
    • 64649086758 scopus 로고    scopus 로고
    • Role of [18F] fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma
    • Zinzani PL, Stefoni V, Tani M, et al. Role of [18F] fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781-1787.
    • (2009) J Clin Oncol , vol.27 , pp. 1781-1787
    • Zinzani, P.L.1    Stefoni, V.2    Tani, M.3
  • 124
    • 18744394609 scopus 로고    scopus 로고
    • Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukemia group B
    • Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003;21:5-15.
    • (2003) J Clin Oncol , vol.21 , pp. 5-15
    • Peterson, B.A.1    Petroni, G.R.2    Frizzera, G.3
  • 125
    • 55949083696 scopus 로고    scopus 로고
    • Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma
    • Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-5169.
    • (2008) J Clin Oncol , vol.26 , pp. 5165-5169
    • Al-Tourah, A.J.1    Gill, K.K.2    Chhanabhai, M.3
  • 126
    • 0029005585 scopus 로고
    • Long-term survival after histologic transformation of low-grade follicular lymphoma
    • Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995;13:1726-1733.
    • (1995) J Clin Oncol , vol.13 , pp. 1726-1733
    • Yuen, A.R.1    Kamel, O.W.2    Halpern, J.3    Horning, S.J.4
  • 127
    • 84875987846 scopus 로고    scopus 로고
    • Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: A report of the Canadian Blood and Marrow Transplant group
    • Villa D, Crump M, Panzarella T, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian Blood and Marrow Transplant group. J Clin Oncol 2013;31:1164-1171.
    • (2013) J Clin Oncol , vol.31 , pp. 1164-1171
    • Villa, D.1    Crump, M.2    Panzarella, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.